Hikma Pharmaceuticals Plc Company Secretary Change (6657X)
2023年12月29日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMHIK
RNS Number : 6657X
Hikma Pharmaceuticals Plc
29 December 2023
Hikma Pharmaceuticals PLC
(the Company)
Company Secretary Change
London, 29 December 2023 - Hikma Pharmaceuticals PLC
(LEI:549300BNS685UXH4JI75) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) announces that Hussein Arkhagha, Chief People Officer and
Company Secretary will step down from his Company Secretary role
from 1 January 2024, and will continue in his role as the Chief
People Officer of Hikma. Helen Middlemist, Deputy Company
Secretary, will be appointed Company Secretary effective same date,
1 January 2024.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Susan Ringdal, EVP Strategic Planning and Global Affairs +44
(0)20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 45 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the North America, the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,800 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
COSFLFSVFLLLFIV
(END) Dow Jones Newswires
December 29, 2023 02:00 ET (07:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
過去 株価チャート
から 4 2024 まで 5 2024
Hikma Pharmaceuticals (LSE:HIK)
過去 株価チャート
から 5 2023 まで 5 2024